RedShift Bioanalytics nets $20M in new financing

By The Science Advisory Board staff writers

October 19, 2021 -- RedShift BioAnalytics (RedShift Bio) has finalized a $20 million series E funding round.

The preferred stock financing round was led by Illumina Ventures, with participation by all of the company's current major investors. RedShiftBio said it would use the proceeds to fund additional commercial expansion and develop new applications and products.

The firm is developing platform technology to enable the measurement of previously undetectable structure changes in biomolecules.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.